JP2005513106A - ヘパリンを保有する眼薬剤 - Google Patents
ヘパリンを保有する眼薬剤 Download PDFInfo
- Publication number
- JP2005513106A JP2005513106A JP2003554209A JP2003554209A JP2005513106A JP 2005513106 A JP2005513106 A JP 2005513106A JP 2003554209 A JP2003554209 A JP 2003554209A JP 2003554209 A JP2003554209 A JP 2003554209A JP 2005513106 A JP2005513106 A JP 2005513106A
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- hyaluronic acid
- eye
- pharmaceutical composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 229920000669 heparin Polymers 0.000 title claims abstract description 54
- 229960002897 heparin Drugs 0.000 title claims abstract description 50
- 229940023490 ophthalmic product Drugs 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 35
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 24
- 230000004054 inflammatory process Effects 0.000 claims abstract description 18
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 16
- 206010013774 Dry eye Diseases 0.000 claims abstract description 16
- 206010061218 Inflammation Diseases 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 41
- 229920002674 hyaluronan Polymers 0.000 claims description 34
- 229960003160 hyaluronic acid Drugs 0.000 claims description 34
- 229940014041 hyaluronate Drugs 0.000 claims description 21
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 20
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 18
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 18
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 12
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 230000007815 allergy Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 206010039705 Scleritis Diseases 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 239000001913 cellulose Chemical class 0.000 claims description 3
- 229920002678 cellulose Chemical class 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical class FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004925 Acrylic resin Chemical class 0.000 claims description 2
- 206010057380 Allergic keratitis Diseases 0.000 claims description 2
- 229920001287 Chondroitin sulfate Chemical class 0.000 claims description 2
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 claims description 2
- 229920002971 Heparan sulfate Polymers 0.000 claims description 2
- 229920001499 Heparinoid Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Chemical class 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Chemical class 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000002554 heparinoid Substances 0.000 claims description 2
- 239000003055 low molecular weight heparin Substances 0.000 claims description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920002401 polyacrylamide Chemical class 0.000 claims description 2
- 229920001223 polyethylene glycol Chemical class 0.000 claims description 2
- 229920002451 polyvinyl alcohol Chemical class 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Chemical class 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Chemical class 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 2
- 238000004904 shortening Methods 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 abstract description 5
- 208000010668 atopic eczema Diseases 0.000 abstract description 5
- 210000001508 eye Anatomy 0.000 description 40
- 210000004087 cornea Anatomy 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000003889 eye drop Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 229940012356 eye drops Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000000744 eyelid Anatomy 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 4
- 229960001008 heparin sodium Drugs 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000004034 viscosity adjusting agent Substances 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004397 blinking Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003885 eye ointment Substances 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000002268 wool Anatomy 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000010393 epithelial cell migration Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- -1 salt hyaluronate Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000012748 slip agent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002125 Sokalan® Chemical class 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- QEVGBDAVCSPCLP-UHFFFAOYSA-N acetic acid;boric acid Chemical compound CC(O)=O.OB(O)O QEVGBDAVCSPCLP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000004321 blink reflex Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Chemical class 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10161149A DE10161149B4 (de) | 2001-12-12 | 2001-12-12 | Verwendung von Heparin-haltigem Ophthalmikum |
| PCT/DE2002/004526 WO2003053452A1 (de) | 2001-12-12 | 2002-12-11 | Heparin-haltiges ophthalmikum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005513106A true JP2005513106A (ja) | 2005-05-12 |
| JP2005513106A5 JP2005513106A5 (enExample) | 2006-02-09 |
Family
ID=7709005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003554209A Pending JP2005513106A (ja) | 2001-12-12 | 2002-12-11 | ヘパリンを保有する眼薬剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050043271A1 (enExample) |
| EP (1) | EP1453523B1 (enExample) |
| JP (1) | JP2005513106A (enExample) |
| CN (1) | CN1604784A (enExample) |
| AT (1) | ATE318607T1 (enExample) |
| AU (1) | AU2002357972A1 (enExample) |
| CA (1) | CA2468775A1 (enExample) |
| DE (2) | DE10161149B4 (enExample) |
| ES (1) | ES2259727T3 (enExample) |
| MX (1) | MXPA04005390A (enExample) |
| WO (1) | WO2003053452A1 (enExample) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534225A (ja) * | 2007-07-23 | 2010-11-04 | アグロ インダストリ ルシュルシェ エ デベロップメンツ エー．アール．ディー． | 皮膚、眼および粘膜の保護機能改善用組成物を製造するためのヒアルロン酸の使用 |
| JP2014159488A (ja) * | 2008-11-20 | 2014-09-04 | Lab Derivati Organici Spa | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
| JP2019511494A (ja) * | 2016-03-07 | 2019-04-25 | ウルサファルム アルツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼科用組成物 |
| JP2019532105A (ja) * | 2016-10-14 | 2019-11-07 | アイ．コム メディカル ゲーエムベーハー | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2020525416A (ja) * | 2017-06-29 | 2020-08-27 | アドヴァイテ エルエルシー． | 眼表面障害の治療及び診断 |
| JP2021511317A (ja) * | 2018-01-18 | 2021-05-06 | ファエス・ファルマ・ソシエダッド・アノニマＦａｅｓ Ｆａｒｍａ， Ｓ．Ａ． | ビラスチン、β−シクロデキストリンおよび少なくとも１種のゲル化剤を含有する眼科用組成物 |
| JP2023060015A (ja) * | 2014-06-10 | 2023-04-27 | ロート製薬株式会社 | 眼科用組成物 |
| WO2024024920A1 (ja) * | 2022-07-29 | 2024-02-01 | マルホ株式会社 | 眼科用組成物 |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| US12303527B2 (en) | 2018-04-18 | 2025-05-20 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001244713A1 (en) * | 2000-04-03 | 2001-10-15 | Santen Pharmaceutical Co. Ltd. | Transporters and drug delivery system by using the same |
| WO2004093878A1 (en) * | 2003-04-16 | 2004-11-04 | Alcon, Inc. | Use of fused pyridazine derivatives for treating dry eye disorders |
| DE10360425A1 (de) * | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung |
| JP2005187407A (ja) * | 2003-12-25 | 2005-07-14 | Lion Corp | アレルギー眼疾患用眼科組成物 |
| DE102004002001A1 (de) | 2004-01-14 | 2005-08-11 | Reinmüller, Johannes, Dr.med. | Mittel zur Behandlung von entzündlichen Erkrankungen |
| DE102005035986B4 (de) * | 2005-07-28 | 2009-10-15 | Bausch & Lomb Incorporated | Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat |
| DE102005055275A1 (de) * | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung |
| DE102006049091A1 (de) * | 2006-10-18 | 2008-04-24 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Emulgatorfreies ophthalmisches Präparat enthaltend Pflanzenöl |
| US20110065643A1 (en) | 2009-06-12 | 2011-03-17 | University Of Southern California | Clusterin Pharmaceuticals and Treatment Methods Using the Same |
| FR2962044B1 (fr) * | 2010-04-21 | 2013-02-22 | Horus Pharma | Emulsion lacrymimetique |
| JP7333919B2 (ja) * | 2017-09-05 | 2023-08-28 | エクセル メッド、エルエルシー | 虚血を治療するためのヘパリン組成物 |
| CN116139067B (zh) * | 2021-11-22 | 2024-03-22 | 华熙生物科技股份有限公司 | 透明质酸锌形成凝胶的方法及含有透明质酸锌的滴眼凝胶及其制备 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3232833A (en) * | 1962-01-17 | 1966-02-01 | Riviere Charles | Heparin containing compositions |
| DE3440352A1 (de) * | 1984-11-05 | 1986-05-07 | Dr. Thilo & Co GmbH, 8029 Sauerlach | Dry-eye-packung |
| JPS635745A (ja) * | 1986-04-04 | 1988-01-11 | アラ−ガン・インコ−ポレイテツド | 角膜創傷治癒用組成物 |
| JPH02167233A (ja) * | 1988-11-10 | 1990-06-27 | Kiyoshi Kita | 眼内手術補助剤 |
| JPH06192130A (ja) * | 1992-09-30 | 1994-07-12 | Union Carbide Chem & Plast Technol Corp | ムコ接着性ポリマー |
| JPH08169835A (ja) * | 1994-07-25 | 1996-07-02 | Lab Medidom Sa | 人工涙として使用するための眼用製剤 |
| DE19547972A1 (de) * | 1995-12-21 | 1997-07-10 | Weropharm Gmbh | Heparin zur Prophylaxe und akuten Therapie der allergischen Konjunktivitis |
| WO2001074330A2 (en) * | 2000-04-04 | 2001-10-11 | Bausch & Lomb Incorporated | Method for treating dry eye |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6479103A (en) * | 1987-06-09 | 1989-03-24 | Lion Corp | External preparation |
| DK505488D0 (da) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | Middel og anvendelse af samme |
| US5141741A (en) * | 1988-12-09 | 1992-08-25 | Lion Corporation | Anti-sunburn skin-care preparation |
| DE19520575A1 (de) * | 1995-06-06 | 1996-12-12 | Permselect Ges Fuer Zellstrukt | Hautwirksame Kombination von Mucopolysacchariden |
| US6372755B2 (en) * | 1997-07-11 | 2002-04-16 | Toray Industries, Inc. | Stable medicinal compositions containing 4,5-epoxymorphinan derivatives |
-
2001
- 2001-12-12 DE DE10161149A patent/DE10161149B4/de not_active Expired - Lifetime
-
2002
- 2002-02-11 US US10/496,330 patent/US20050043271A1/en not_active Abandoned
- 2002-12-11 CN CNA028250079A patent/CN1604784A/zh active Pending
- 2002-12-11 ES ES02791625T patent/ES2259727T3/es not_active Expired - Lifetime
- 2002-12-11 MX MXPA04005390A patent/MXPA04005390A/es active IP Right Grant
- 2002-12-11 EP EP02791625A patent/EP1453523B1/de not_active Expired - Lifetime
- 2002-12-11 AT AT02791625T patent/ATE318607T1/de active
- 2002-12-11 AU AU2002357972A patent/AU2002357972A1/en not_active Abandoned
- 2002-12-11 DE DE50205968T patent/DE50205968D1/de not_active Expired - Lifetime
- 2002-12-11 WO PCT/DE2002/004526 patent/WO2003053452A1/de not_active Ceased
- 2002-12-11 JP JP2003554209A patent/JP2005513106A/ja active Pending
- 2002-12-11 CA CA002468775A patent/CA2468775A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3232833A (en) * | 1962-01-17 | 1966-02-01 | Riviere Charles | Heparin containing compositions |
| DE3440352A1 (de) * | 1984-11-05 | 1986-05-07 | Dr. Thilo & Co GmbH, 8029 Sauerlach | Dry-eye-packung |
| JPS635745A (ja) * | 1986-04-04 | 1988-01-11 | アラ−ガン・インコ−ポレイテツド | 角膜創傷治癒用組成物 |
| JPH02167233A (ja) * | 1988-11-10 | 1990-06-27 | Kiyoshi Kita | 眼内手術補助剤 |
| JPH06192130A (ja) * | 1992-09-30 | 1994-07-12 | Union Carbide Chem & Plast Technol Corp | ムコ接着性ポリマー |
| JPH08169835A (ja) * | 1994-07-25 | 1996-07-02 | Lab Medidom Sa | 人工涙として使用するための眼用製剤 |
| DE19547972A1 (de) * | 1995-12-21 | 1997-07-10 | Weropharm Gmbh | Heparin zur Prophylaxe und akuten Therapie der allergischen Konjunktivitis |
| WO2001074330A2 (en) * | 2000-04-04 | 2001-10-11 | Bausch & Lomb Incorporated | Method for treating dry eye |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534225A (ja) * | 2007-07-23 | 2010-11-04 | アグロ インダストリ ルシュルシェ エ デベロップメンツ エー．アール．ディー． | 皮膚、眼および粘膜の保護機能改善用組成物を製造するためのヒアルロン酸の使用 |
| JP2014159488A (ja) * | 2008-11-20 | 2014-09-04 | Lab Derivati Organici Spa | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 |
| JP2023060015A (ja) * | 2014-06-10 | 2023-04-27 | ロート製薬株式会社 | 眼科用組成物 |
| JP2019511494A (ja) * | 2016-03-07 | 2019-04-25 | ウルサファルム アルツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼科用組成物 |
| JP2019532105A (ja) * | 2016-10-14 | 2019-11-07 | アイ．コム メディカル ゲーエムベーハー | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2022153583A (ja) * | 2016-10-14 | 2022-10-12 | アイ．コム メディカル ゲーエムベーハー | 角結膜のホメオスタシスを確立、回復及び維持するための方法 |
| JP2020525416A (ja) * | 2017-06-29 | 2020-08-27 | アドヴァイテ エルエルシー． | 眼表面障害の治療及び診断 |
| JP2021511317A (ja) * | 2018-01-18 | 2021-05-06 | ファエス・ファルマ・ソシエダッド・アノニマＦａｅｓ Ｆａｒｍａ， Ｓ．Ａ． | ビラスチン、β−シクロデキストリンおよび少なくとも１種のゲル化剤を含有する眼科用組成物 |
| JP7309729B2 (ja) | 2018-01-18 | 2023-07-18 | ファエス・ファルマ・ソシエダッド・アノニマ | ビラスチン、β－シクロデキストリンおよび少なくとも１種のゲル化剤を含有する眼科用組成物 |
| US12303527B2 (en) | 2018-04-18 | 2025-05-20 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| WO2024024920A1 (ja) * | 2022-07-29 | 2024-02-01 | マルホ株式会社 | 眼科用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1453523B1 (de) | 2006-03-01 |
| CA2468775A1 (en) | 2003-07-03 |
| DE10161149B4 (de) | 2007-03-08 |
| WO2003053452A1 (de) | 2003-07-03 |
| DE50205968D1 (de) | 2006-04-27 |
| DE10161149A1 (de) | 2003-06-26 |
| US20050043271A1 (en) | 2005-02-24 |
| CN1604784A (zh) | 2005-04-06 |
| MXPA04005390A (es) | 2005-10-18 |
| ATE318607T1 (de) | 2006-03-15 |
| AU2002357972A1 (en) | 2003-07-09 |
| ES2259727T3 (es) | 2006-10-16 |
| EP1453523A1 (de) | 2004-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3994089B2 (ja) | 眼科学および鼻科学における適用のための薬学的組成物 | |
| JP7432654B2 (ja) | 人工涙液、コンタクトレンズ及び薬剤担体組成物並びにその使用方法 | |
| JP2005513106A (ja) | ヘパリンを保有する眼薬剤 | |
| Nanjawade et al. | RETRACTED: In situ-forming hydrogels for sustained ophthalmic drug delivery | |
| RU2687275C2 (ru) | Слезозаменитель, содержащий гиалуронат натрия и карбоксиметилцеллюлозу | |
| Middleton et al. | Ocular bioadhesive delivery systems | |
| JP2008520671A (ja) | 眼科用組成物および眼の治療方法 | |
| CN101312711B (zh) | 不含右泛醇、钙离子和磷酸盐的药物组合物以及钙螯合剂和眼科相容粘度调节剂的应用 | |
| Bernatchez et al. | Use of hyaluronic acid in ocular therapy | |
| CN110090294A (zh) | 具有改善的干燥保护和保留的眼用组合物 | |
| US5200180A (en) | Pharmaceutical composition for the treatment of the human eye | |
| CN113332233B (zh) | 热凝胶化人工泪液 | |
| WO2006044155A2 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| RU2302231C1 (ru) | Глазные капли для лечения синдрома сухого глаза | |
| DE10360425A1 (de) | Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung | |
| EA018202B1 (ru) | Офтальмологический гель и способ его приготовления | |
| EP3452010A1 (en) | Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof | |
| CN120661442A (zh) | 一种滴眼液的组合物及其制备方法和应用 | |
| Mundada | Update on Polymers for Ocular Drug Delivery | |
| CA2972212C (en) | AGENT AND IMPROVEMENT OF SUBJECTIVE OCULAR SYMPTOMS AND ASSOCIATED METHOD | |
| JP2006503012A (ja) | パパベリン様血管拡張剤の用途および薬剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090818 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100427 |